Q2
DCOY — Q2 2026 Financial Report Analysis
Decoy Therapeutics' Q2 2026 net loss widened to $2.37M as the merged company funds its nasal antiviral platform. About $5.6M of usable cash, a going-concern warning and repriced warrants put financing ahead of science.